该适应症的获批主要是基于一项关键临床试验，入组对象为未接受过系统性抗肿瘤治疗、经组织学或细 胞学确诊的不可切除的局部晚期或转移性胰腺癌患者。在2024年美国临床肿瘤学会(ASCO)年会已披露 的结果显示，该产品用于晚期胰腺癌一线治疗可显著延长无进展生存期(PFS)(风险比(HR)为0.55，疾病 进展或死亡风险降低45%)，在客观缓解率(ORR)、缓解持续时间(DOR)及总生存期(OS)方面均呈现获益 趋势，且安全性良好，相比普通制剂实现了减毒增效的作用。 该产品已于2023年9月15日在中国获批上市，首个获批的适应症为与5-氟尿嘧啶(5-FU)和亚叶酸(LV)联 合用于接受吉西他滨治疗后进展的转移性胰腺癌患者，为国内企业首个获批上市的盐酸伊立替康脂质体 注射液。本次获批的适应症为该产品在中国获批的第二个适应症，亦是伊立替康脂质体注射液在国内首 次获批用于胰腺癌一线治疗。目前，该产品用于胰腺癌术后辅助治疗的关键注册III期临床试验正在进行 中。 石药集团(01093)发布公告，集团开发的盐酸伊立替康脂质体注射液(商品名：多恩益)的新适应症已获得 中华人民共和国国家药品监督管理局上市批准。本次获批的新适应症为与 ...

格隆汇12月12日丨石药集团(01093.HK)公告，集团开发的盐酸伊立替康脂质体注射液(商品名：多恩益) ("该产品")的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的新适应症为与 奥沙利铂、5-氟尿嘧啶(5-FU)和亚叶酸(LV)联合用于转移性胰腺癌患者的一线治疗("该适应症")。 该产品已于2023年9月15日在中国获批上市，首个获批的适应症为与5-氟尿嘧啶(5-FU)和亚叶酸(LV)联 合用于接受吉西他滨治疗后进展的转移性胰腺癌患者，为国内企业首个获批上市的盐酸伊立替康脂质体 注射液。本次获批的适应症为该产品在中国获批的第二个适应症，亦是伊立替康脂质体注射液在国内首 次获批用于胰腺癌一线治疗。目前，该产品用于胰腺癌术后辅助治疗的关键注册III期临床试验正在进行 中。 该适应症的获批主要是基于一项关键临床试验，入组对象为未接受过系统性抗肿瘤治疗、经组织学或细 胞学确诊的不可切除的局部晚期或转移性胰腺癌患者。在2024年美国临床肿瘤学会(ASCO)年会已披露 的结果显示，该产品用于晚期胰腺癌一线治疗可显著延长无进展生存期(PFS)(风险比(HR)为0.55，疾病 进展或死亡风险降低45 ...

fund 该适应症的获批主要是基于一项关键临床试验，入组对象为未接受过系统性抗肿瘤治疗、经组织学或细 胞学确诊的不可切除的局部晚期或转移性胰腺癌患者。在2024年美国临床肿瘤学会(ASCO)年会已披露 的结果显示，该产品用于晚期胰腺癌一线治疗可显著延长无进展生存期(PFS)(风险比(HR)为0.55，疾病 进展或死亡风险降低45%)，在客观缓解率(ORR)、缓解持续时间(DOR)及总生存期(OS)方面均呈现获益 趋势，且安全性良好，相比普通制剂实现了减毒增效的作用。 该产品已于2023年9月15日在中国获批上市，首个获批的适应症为与5-氟尿嘧啶(5-FU)和亚叶酸(LV)联 合用于接受吉西他滨治疗后进展的转移性胰腺癌患者，为国内企业首个获批上市的盐酸伊立替康脂质体 注射液。本次获批的适应症为该产品在中国获批的第二个适应症，亦是伊立替康脂质体注射液在国内首 次获批用于胰腺癌一线治疗。目前，该产品用于胰腺癌术后辅助治疗的关键注册III期临床试验正在进行 中。 （原标题：石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准） 智通财经APP讯，石药集团(01093)发布公告，集团开发的盐 ...

格隆汇12月12日｜据一财，年底临近，跨国制药巨头布局下一代减重药的步伐没有放缓迹象。日前，礼 来公布了一项新型减重药的最新数据；而辉瑞也再次出手收购中国公司的下一代GLP-1类药物。 另一方 面，随着礼来的替尔泊肽将于2026年纳入医保，以及诺和诺德的司美格鲁肽在中国的核心专利即将到 期，国内的GLP-1类代谢药市场的整体格局也将"变天"。 业内人士预计，GLP-1药物未来的供给将远大 于此前一轮药企扎堆的PD-1靶点药物。而随着大量仿制药的上市，2026年，一场GLP-1药物的价格战也 即将打响。 据不完全统计，截至目前，已有8款国产司美格鲁肽获上市受理，分别来自惠升生物、成都 倍特、石药集团、杭州中美华东、珠海联邦、齐鲁、丽珠、九源基因。 ...

Investment Rating - The report maintains an "Optimistic" rating for the industry and a "Buy" rating for Heng Rui Medicine (600276) [52] Core Insights - The newly released basic medical insurance drug directory and the first commercial health insurance innovative drug directory support the development of innovative drugs and promote the complementary relationship between commercial health insurance and basic medical insurance [9][12] - A total of 114 new drugs have been added to the directory, including 50 first-class innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [11][12] - The report emphasizes the importance of monitoring the volume growth of pharmaceutical companies' products after entering the insurance directory and the investment opportunities arising from the optimization of payment structures for innovative drug companies [51] Industry News - The new basic medical insurance drug directory and the first commercial health insurance innovative drug directory were published, with the new directory set to take effect on January 1, 2026 [9] - The first commercial health insurance innovative drug directory includes 19 drugs, which complement the basic medical insurance and support the establishment of a multi-tiered medical security system [12] - The first CDK2/4/6 inhibitor developed by China Biopharmaceutical has been approved for market launch, indicating advancements in innovative drug development [14] Company Announcements - Heng Rui Medicine has successfully included several drugs in the national medical insurance directory through negotiations, enhancing its market position [31] - Stone Pharmaceutical Group has received acceptance for its second marketing authorization application for Semaglutide injection [29] - Junshi Biosciences has had its new drug application for the injection of Nocadizumab accepted [32] Market Review - For the week of December 5 to December 11, 2025, the SW Pharmaceutical and Biological Index fell by 0.78%, with most sub-sectors experiencing declines [40] - As of December 11, 2025, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) was 50.70, with a valuation premium of 265% relative to the CSI 300 [44] Weekly Strategy - The report suggests focusing on the growth potential of pharmaceutical companies' products after entering the insurance directory and the investment opportunities in the CXO and upstream life sciences sectors [51]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the high-volatility Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 1%, potentially ending a four-day losing streak. Notably, this week has seen a net subscription of over 130 million yuan, indicating increased buying interest [1][6]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a cumulative net subscription of over 130 million yuan this week [1][6]. - As of November 30, the ETF's scale reached 2.142 billion yuan, with an average daily trading volume of 458 million yuan since its listing, making it the largest and most liquid among its peers [10]. Group 2: Sector Dynamics - The leading stock, Kangfang Biologics, surged over 6.8%, while other notable stocks like Innovent Biologics and BeiGene also saw gains of over 2% and 1%, respectively [8]. - Kangfang Biologics has received FDA approval to conduct a Phase III clinical trial for its PD-1/CTLA-4 dual-specific antibody, indicating significant advancements in innovative drug development [3][8]. Group 3: Investment Insights - A report from Ping An Securities suggests that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipelines, high-potential single products, and leading technology platforms [3][8]. - The Hong Kong innovative drug sector has been in a correction phase since early September, enhancing the cost-effectiveness of investments in this area [3][8]. Group 4: Index Characteristics - The underlying index for the ETF, the Hang Seng Stock Connect Innovative Drug Select Index, has a significant concentration of leading stocks, with the top ten holdings accounting for over 72% of the index weight [4][9]. - The index is designed to exclude CXO companies, focusing solely on innovative drug developers, which enhances its purity and comprehensiveness [9].

Core Viewpoint - The pharmaceutical company Shiyao Innovation is preparing for an IPO on the Hong Kong Stock Exchange, driven by a need to raise funds amid declining traditional business performance and challenges in transitioning to innovative drug development [2][18][35]. Group 1: Financial Performance - Shiyao Innovation has experienced a continuous decline in revenue over the past three years, with revenues of 28.38 billion RMB, 25.39 billion RMB, and 19.81 billion RMB from 2022 to 2024, respectively [8][24]. - The company's net profit has turned from a profit of 2.94 billion RMB in 2022 to a loss of 3 billion RMB in 2024, with a further loss of 2.26 billion RMB reported in the first seven months of 2025 [9][24][25]. - The gross profit margins have also decreased, with figures of 46.8%, 45.6%, and 41.8% from 2022 to 2024 [24][26]. Group 2: Business Transition - Shiyao Innovation is transitioning from a traditional raw material supplier to an innovative drug developer, acquiring subsidiaries like Jushi Biopharma to enhance its product offerings in the biopharmaceutical sector [4][12][32]. - The company has two commercialized antibody drugs and two mRNA vaccines, with 15 drugs in clinical stages, but the contribution of biopharmaceutical products to revenue remains low, accounting for less than 5% in 2024 [12][29]. - R&D expenses have surged, with a projected increase of 25.51% to 8.43 billion RMB in 2024, representing 42.5% of total revenue, which is a significant factor in the company's losses [12][29]. Group 3: Corporate Governance and Market Position - The company is controlled by Cai Dongchen, who has a net worth of 15.5 billion RMB, and holds 73.8% of Shiyao Innovation through Enbipu Pharmaceutical [30][31]. - Recent corporate governance issues have arisen, including insider trading scandals involving former executives, which have raised concerns about internal controls within the company [16][33][34]. - Shiyao Innovation's IPO is seen as a strategy to alleviate financial pressures during its transition to innovative drug development, with traditional business still accounting for a significant portion of its revenue [35].

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The Hang Seng Technology Index fell by 0.83%, with a market turnover of HKD 182.48 billion [1] - In the US market, the Dow Jones increased by 1.34% to a record high of 48,704.01 points, while the S&P 500 rose by 0.21% [2] Investment Opportunities - The report emphasizes the attractiveness of low-valuation, high-dividend sectors in the Hong Kong market, suggesting that these areas remain appealing for capital allocation [3] - Key sectors to focus on include artificial intelligence, semiconductors, industrial software, and state-owned enterprises with low valuations and high dividends [3] - The report highlights the potential for long-term growth in technology sectors, particularly in companies leading in semiconductors and robotics [3] Company Performance - Meituan-W and Xiaomi Group-W saw increases of 1.50% and 0.96% respectively, while Hua Hong Semiconductor and Horizon Robotics experienced declines of 4.80% and 3.34% [1] - Oracle's stock dropped nearly 11% following concerns over high valuations in the tech sector, despite the overall market benefiting from the Federal Reserve's interest rate cuts [2] - The report suggests monitoring companies in the copper mining and smelting sectors, such as China Nonferrous Mining (1258.HK) and Luoyang Molybdenum (3993.HK), due to rising copper prices driven by demand from AI data centers and electric vehicles [9]

港股创新药连续调整吸引资金关注，12月12日，核心标的港股通创新药ETF（520880）场内价格下探近 5个月低点，场内宽幅溢价，彰显买盘势力！此前4日已有资金连续进场，累计增仓逾1.3亿元。 | 册 多日 1分 * | | | | F9 盘前盘后 盈加 九转 图技 工具 @ 0 | | | | | | | 港股通创新药ETF O | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.544 | | | 520880[種設通创新的ETF] 10:20 价 0.537 涨跌 -0.001(-0.19%) | | | 1.12% | | | 0.537 -0.001 -0.19% | | 520880 | | | | 0.543 | | | | | | 0.93% | | | SSE CNY 10:20:39 交易中 查看L2全国 | | | T+0 De / 0 + | | | | | | | | | | 净值市势 | | 华宜恒生港股通创新商 | | 实时中购藏网体息申购 ...

Group 1 - Jin Cheng Pharmaceutical's actual controller received an administrative penalty from the China Securities Regulatory Commission (CSRC) for stock manipulation, leading to the resignation of Chairman Zhao Yeqing and exposing governance issues within the company [1] - Zhao Yeqing, Wang Zhen, and Liu Feng were fined a total of 3 million yuan, with Zhao facing a 4-year market ban and Wang a 3-year ban [1] Group 2 - Stone Pharmaceutical Innovation, a spin-off from Stone Pharmaceutical Group, submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, focusing on biopharmaceuticals and health products [2] - Despite facing performance pressure in 2024, the company has a strong growth potential in its biopharmaceutical business and a rich R&D pipeline, aiming to leverage the Hong Kong market for financing [2] Group 3 - JunSai Bio submitted its prospectus to the Hong Kong Stock Exchange, highlighting its core product GC101, a novel tumor-infiltrating lymphocyte (TIL) therapy that does not require intensive chemotherapy or IL-2 administration [3] - GC101 has the potential to be the first approved TIL therapy in China, but its commercialization model remains unproven amid increasing competition in the TIL therapy space [3] Group 4 - Innovent Biologics announced that its new generation TRK inhibitor, Iruvotrib, received approval from the National Medical Products Administration (NMPA) for treating adult and adolescent patients with NTRK fusion gene-positive solid tumors [4] - This approval marks the first domestically developed new generation TRK inhibitor in China, offering improved efficacy and safety compared to first-generation TRK inhibitors [4] Group 5 - Yunding New Medicine announced strategic cooperation agreements with Haisen Biopharmaceutical, including a commercialization service agreement and a licensing agreement, aimed at enhancing operational efficiency and commercial capabilities [5] - These agreements are expected to strengthen Yunding's commercialization capabilities and expand its cardiovascular pipeline, aligning with growth trends in the sector [5]